Loading
A phase 3 trial of Cediranib in Ovarian cancer, run by Medical Research Council, with a status the registry has not verified recently.
An RCT of Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer is a phase 3 interventional study registered as NCT00532194 by Medical Research Council, with 486 participants planned, started 2007-07 and due to reach its primary completion in 2013-04. Interventions recorded: cediranib. Conditions recorded: Ovarian Cancer.
Linked to the drug Cediranib because the registry names it among its interventions and Ovarian cancer among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Platinum-sensitive ovarian cancer, Ovarian cancer and the tag pipeline.
Shares Cediranib and the tag pipeline.
Shares Platinum-sensitive ovarian cancer, Ovarian cancer and the tag pipeline.
Shares Platinum-sensitive ovarian cancer, Ovarian cancer and the tag pipeline.
Shares Cediranib and the tag pipeline.
Shares MRC Clinical Trials Unit at UCL and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/